Skip to main content

Table 2 Geometric mean concentrations of pertussis antibodies in maternal and infants’ blood at birth

From: Efficacy and safety of pertussis vaccination for pregnant women – a systematic review of randomised controlled trials and observational studies

 

Study design

Intervention/ exposuretype, mean gestational week at vaccination (range)

Com-parator

Maternal blood birth

Infant cord blood at birth

n: Vaccine/control

Vaccine Geometric mean (95% CI)

Control Geometric mean (95% CI)

Ratio of geometric means (95% CI)

p

n: Vaccine/control

Vaccine Geometric mean (95% CI)

Control Geometric mean (95% CI)

Ratio of geometric means (95% CI)

p

PT (EU or IU/ml)*

 Munoz [31]

RCT

Tdap -- (30–32)

placebo

33/14

51.0 (37.1–70.1)

9.1 (4.6–17.8)

5.6 (3.0–10.5)

<0.001

31/14

68.8 (52.1–90.8)

14.0 (7.3–26.9)

4.9 (2.8–8.7)

<0.001

 Hoang [30]

RCT

Tdap 26 (19–35)

TT

51/47

17.3 (13.0–22.0)

5.7 (4.3–7.6)

3.0 (2.1–4.4)

<0.001

50/47

21.0 (16.0–28.0)

7.2 (5.6–9.4)

2.9 (2.0–4.3)

<0.001

 Abu Raya [26]

PCS

Tdap -- (≥ 20)

no vac.

61/20

16.9 (10.5–27.0)

0.7 (0.3–1.8)

22.8 (8.8–58.7)

<0.001

61/20

17.81 (10.67–29.74)

1.12 (0.41–3.02)

15.9 (5.6–45.1)

<0.001

  (subset)

 

(2736)

 

51/20

16.4 (9.6–28.0)

0.7 (0.3–1.8)

22.1 (8.1–60.0)

<0.001

51/20

17.3 (9.5–31.5)

1.12 (0.4–3.0)

15.4 (5.0–47.6)

<0.001

  (subset)

 

(≥ 37)

 

7/20

28.1 (12.5–63.4)

0.7 (0.3–1.8)

38.0 (8.2–174.9)

<0.001

7/20

21.12 (7.9–56.2)

1.12 (0.4–3.0)

18.9 (3.3–108.1)

<0.001

 Hardy-Fairbanks [33]

PCS

Tdap – (anytime)

no vac.

5/53

14.3 (−-)

7.5 (−-)

1.9 (−-)

5/53

33.5 (−-)

12.6 (−-)

2.7 (−-)

 Maertens [29]

PCS

Tdap 29 (22–33)

no vac.

56/41

31.4 (26.0–38.0)

6.4 (4.3–9.6)

4.9 (3.3–7.3)

<0.001

58/41

100.7 (82.0–123.0)

12.4 (8.0–19.0)

8.1 (5.3–12.5)

<0.001

 Healy [34]

RCS

Tdap 9 (1–29)

before

19/86

10.5 (6.4–17.1)

14.0 (11.1–17.7)

0.8 (0.4–1.3)

0.29

19/86

17.3 (11.1–26.8)

16.7 (13.2–21.0)

1.0 (0.6–1.8)

0.90

 Gall [5]

RCS

Tdap -- (anytime)

no vac.

     

52/52

Mean 28.2 (SE 2.8)

Mean 11.01 (SE 1.8)

MD 17.2 (10.7–23.8)

 

FHA (EU or IU/ml)

 Munoz [31]

RCT

Tdap -- (30–32)

placebo

33/14

184.8 (142.8–239.1)

21.9 (10.9–44.1)

8.4 (4.8–15.0)

<0.001

31/14

234.2 (184.6–297.3)

25.1 (10.5–60.3)

9.3 (4.9–17.6)

<0.001

 Hoang [30]

RCT

Tdap 26 (19–35)

TT

49/47

139.0 (109.0–176.0)

17.3 (14.0–21.4)

8.0 (5.8–11.0)

<0.001

49/46

93.0 (65.0–133.0)

27.3 (20.9–36.7)

3.4 (2.2–5.4)

<0.001

 Abu Raya [26]

PCS

Tdap -- (≥ 20)

no vac.

61/20

187.4 (162.9–215.7)

13.4 (8.9–20.3)

14.0 (10.0–19.4)

<0.001

61/20

190.2 (160.9–224.8)

17.1 (10.2–28.7)

11.1 (7.4–16.6)

<0.001

  (subset)

 

(2736)

 

51/20

192.0 (165.9–222.3)

13.4 (8.9–20.3)

14.3 (10.2–20.0)

<0.001

51/20

196.7 (163.4–236.9)

17.1 (10.2–28.7)

11.5 (7.5–17.6)

<0.001

  (subset)

 

(≥ 37)

 

7/20

155.8 (109.3–222.2)

13.4 (8.9–20.3)

11.6 (5.7–23.7)

<0.001

7/20

138.0 (97.6–195.2)

17.1 (10.2–28.7)

8.1 (3.3–19.5)

<0.001

 Hardy-Fairbanks [33]

PCS

Tdap – (anytime)

no vac.

5/53

32.5 (−-)

9.6 (−-)

3.4 (−-)

5/53

66.1 (−-)

15.9 (−-)

4.2 (−-)

 Maertens [29]

PCS

Tdap 29 (22–33)

no vac.

56/41

107.0 (91.0–126.0)

21.4 (16.6–27.5)

5.0 (3.8–6.6)

<0.001

58/41

140.0 (109.0–180.0)

27.5 (21.5–35.0)

5.1 (3.6–7.3)

<0.001

 Healy [34]

RCS

Tdap 9 (1–29)

before

19/86

49.3 (28.4–85.8)

50.9 (40.6–63.9)

1.0 (0.6–1.7)

0.91

19/86

87.6 (56.3–136.4)

73.0 (57.6–92.6)

1.2 (0.7–2.1)

0.51

 Gall [5]

RCS

Tdap -- (anytime)

no vac.

     

52/52

Mean 104.2 (SE 21.7)

Mean 26.8 (SE 4.0)

MD 77.3 (33.6–121.0)

<0.001

PRN (EU or IU/ml)

 Munoz [31]

RCT

Tdap -- (30–32)

placebo

45/35

184.5 (110.2–308.8)

12.2 (5.2–28.4)

15.1 (5.9–38.6)

<0.001

35/35

219.0 (134.4–357.0)

14.4 (5.4–38.4)

15.2 (5.9–39.3)

<0.001

 Hoang [30]

RCT

Tdap 26 (19–35)

TT

49/48

111.0 (76.0–163.0)

9.4 (6.9–12.5)

11.8 (7.3–19.1)

<0.001

49/47

124 (86–179)

13.9 (10.5–18.2)

8.9 (5.6–14.1)

<0.001

 Abu Raya [26]

PCS

Tdap -- (≥ 20)

no vac.

61/20

166.0 (125.7–219.4)

8.5 (3.5–20.3)

19.6 (10.0–38.6)

<0.001

61/20

162.1 (120.4–218.2)

10.6 (4.5–25.3)

15.3 (7.6–30.7)

<0.001

  (subset)

 

(2736)

 

51/20

164.0 (119.5–225.1)

8.5 (3.5–20.3)

19.4 (9.4–39.9)

<0.001

51/20

161.5 (114.7–227.5)

10.6 (4.5–25.3)

15.2 (7.2–32.1)

<0.001

  (subset)

 

(≥ 37)

 

7/20

181.6 (65.5–503.0)

8.5 (3.5–20.3)

21.5 (4.5–101.4)

<0.001

7/20

172.9 (68.7–434.8)

10.6 (4.5–25.3)

16.3 (3.5–75.0)

<0.001

 Hardy-Fairbanks [33]

PCS

Tdap -- (anytime)

no vac.

5/53

24.4 (−-)

6.4 (−-)

3.8 (−-)

5/53

48.5 (−-)

8.9 (−-)

5.5 (−-)

 Maertens [29]

PCS

Tdap 29 (22–33)

no vac.

57/41

602.0 (485.5–747.0)

18.0 (13.0–24.0)

33.4 (23.4–47.9)

<0.001

57/41

697.0 (573.0–848.0)

21.0 (15.5–28.0)

33.2 (23.7–46.5)

<0.001

 Healy [34]

RCS

Tdap 9 (1–29)

before

19/86

40.4 (18.9–87.3)

39.5 (28.3–55.0)

1.0 (0.5–2.2)

0.96

19/86

70 (32.5–150.5)

41.7 (81.6–4.07)

1.2 (0.5–2.6)

0.65

 Gall [5]

RCS

Tdap -- (anytime)

no vac.

     

52/52

Mean 333.0 (SE 56.4)

Mean 24.7 (SE 5.8)

MD 308.3(195.8–420.0)

<0.001

FIM (EU or IU/ml)

 Munoz [31]

RCT

Tdap -- (30–32)

no vac.

11/38

1485.7 (979.9–2252.6)

34.9 (16.3–74.8)

42.6 (19.5–93.1)

<0.001

15/32

1867.0 (1211.7–2876.8)

51.8 (22.8–118)

36.0 (15.8–82.1)

<0.001

 Hardy-Fairbanks [33]

PCS

Tdap -- (anytime)

no vac.

5/53

360.3 (−-)

17.7 (−-)

20.4 (−-)

5/53

912.9 (−-)

25.7 (−-)

35.5 (−-)

 Healy [34]

RCS

Tdap 9 (1–29)

before

11/38

103.1 (42.7–249.0)

138.2 (97.2–196.5)

0.7 (0.3–1.7)

0.49

15/32

191.8 (84.5–435.7)

182.6 (127.7–261.2)

1.1 (0.5–2.4)

0.91

 Gall [5]

RCS

Tdap -- (anytime)

no vac.

51/26

    

49/21

Mean 11,989.0 (SE 189.9)

Mean 82.8 (SE 14.59)

MD 1116.2 (738.3–1494.0)

<0.001

  1. RCT randomised control trial, PCS prospective cohort study, RCS retrospective cohort study, Tdap a combined tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine, TdaP-IPV a combined tetanus, diphtheria, 5-component acellular pertussis, inactivated polio vaccine, TT tetanus toxoid (tetanus only vaccine), SD standard deviation, MD mean difference, CI confidence interval, PT pertussis toxin, FHA filamentous hemagglutinin, PRN pertactin, FIM fimbriae types 2 and 3; no vac, not receiving Tdap or pertussis-containing vaccine during pregnancy; before, Tdap before pregnancy; before, Tdap before pregnancy; −-, data not reported or not calculable. *1 EU = 1 IU